Evidence map›Paper›PMID 40130849›Full record

ArticleMicrobiology spectrum2025

D-enantiomeric antibiofilm peptides effective against anaerobic

Jennifer Varin-Simon, Evan F Haney, Marius Colin, Frédéric Velard, Sophie C Gangloff, Robert E W Hancock, Fany Reffuveille

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Jennifer Varin-SimonUniversité de Reims Champagne-Ardenne, BIOS, Reims, Grand Est, France.ORCID 0000-0003-0421-5503
Evan F HaneyAsep Medical Inc./ABT Innovations Inc., Victoria, British Columbia, Canada.
Marius ColinUniversité de Reims Champagne-Ardenne, BIOS, Reims, Grand Est, France.
Frédéric VelardUniversité de Reims Champagne-Ardenne, BIOS, Reims, Grand Est, France.
Sophie C GangloffUniversité de Reims Champagne-Ardenne, BIOS, Reims, Grand Est, France.
Robert E W HancockAsep Medical Inc./ABT Innovations Inc., Victoria, British Columbia, Canada.ORCID 0000-0001-5989-8503
Fany ReffuveilleUniversité de Reims Champagne-Ardenne, BIOS, Reims, Grand Est, France.ORCID 0000-0002-0753-3761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of antibiotic resistance, biofilm formation, and internalization by host cells contribute to a high risk of chronic infections, highlighting the necessity to develop novel therapeutic strategies. Identification of natural host defense peptides (HDPs) with promising antimicrobial and antibiofilm activities led to the development of synthetic peptides with broad-spectrum efficacy. However, few studies have examined their effect on anaerobic bacterial species. This study aimed to test the effect of synthetic HDPs on

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesBiofilmsPropionibacteriaceaePropionibacterium acnesBacterial AdhesionHumansMicrobial Sensitivity TestsProsthesis-Related InfectionsAnti-Bacterial AgentsAntimicrobial PeptidesbiofilmCutibacterium acneshost defense peptideprosthesis joint injection

Identifiers

PMID40130849
PMCPMC12053997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.